Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$4,793 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
4.7
Industry P/E
--
EV/EBITDA
-14.1
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-2.7
Face value
--
Shares outstanding
203,532,180
CFO
$-559.31 Mln
EBITDA
$-527.71 Mln
Net Profit
$-678.25 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Immunovant Inc (IMVT)
| -3.6 | -11.6 | -3.6 | 61.2 | 16.5 | 7.8 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Immunovant Inc (IMVT)
| 2.6 | -41.0 | 137.4 | 108.3 | -81.6 | 191.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Immunovant Inc (IMVT)
|
24.5 | 4,793.2 | 0.2 | -464.2 | -301,183.8 | -58.2 | -- | 4.7 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating... polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. Address: 320 West 37th Street, New York, NY, United States, 10018 Read more
Executive Chairperson of the Board
Dr. Frank M. Torti M.B.A., M.D.
Executive Chairperson of the Board
Dr. Frank M. Torti M.B.A., M.D.
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Immunovant Inc (IMVT) is $24.50 (NASDAQ) as of 02-Apr-2026 18:52 EDT. Immunovant Inc (IMVT) has given a return of 16.46% in the last 3 years.
Since, TTM earnings of Immunovant Inc (IMVT) is negative, P/E ratio is not available.
The P/B ratio of Immunovant Inc (IMVT) is 4.74 times as on 31-Mar-2026, a 19 premium to its peers’ median range of 3.98 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-6.28
|
3.67
|
|
2024
|
-17.19
|
7.22
|
|
2023
|
-9.04
|
5.26
|
|
2022
|
-3.87
|
1.29
|
|
2021
|
-13.14
|
3.61
|
The 52-week high and low of Immunovant Inc (IMVT) are Rs 29.25 and Rs 12.72 as of 05-Apr-2026.
Immunovant Inc (IMVT) has a market capitalisation of $ 4,793 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Immunovant Inc (IMVT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.60
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.